Patent · US Active

Recombinant Hansenula polymorpha-based high dosage hepatitis B vaccine

US10821174B2 · kind B2 · utility

1Cited by

1References

11Claims

0Family size

Assignee

Hemu Wang · CN

Inventors

Hemu Wang · Tianjin, CN
Changhua Wang · Sichuan, CN
Jun Yang · Beijing, CN

Key dates

Filing date	Mar 16, 2017
Grant date	Nov 3, 2020
Priority date	—
Expiry date	Apr 17, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12R2001/78
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided is a recombinant Hansenula polymorpha-based high dosage hepatitis B vaccine, an HBsAg pure stock solution yield of a recombinant Hansenula polymorpha fermentation broth used for producing the hepatitis B vaccine being 300 mg/L-400 mg/L.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.